Diabetes-Related Cognitive Impairment Diseases

Dear Colleagues,

This Special Issue is the continuation of our previous Special Issue “Diabetes and Dementia”, which was published in 2022.

Although there is worldwide interest and concern regarding dementia, preventive and therapeutic strategies have not yet been established to combat it. Moreover, there has been an accelerated increase in the prevalence of type 2 diabetes in aging populations globally. Type 2 diabetes is an epidemiological risk factor for Alzheimer’s disease and vascular cognitive impairment, which are the two major causes of dementia. Therefore, there exists an urgent need to prevent and improve the detrimental relationship between diabetes and dementia, as well as to develop predictive markers and effective treatment strategies for dementia.

The mechanisms underlying diabetes-related cognitive impairment remain unclear; however, accumulating evidence emphasizes the pathological implications of multifactorial pathways in the development of neurodegeneration in diabetic conditions, such as oxidative stress due to hyperglycemia, microvascular damage, central insulin resistance, amyloid-β accumulation, tau hyperphosphorylation, neuroinflammation, and mitochondrial dysfunction. Furthermore, recent advances in clinical studies have disclosed the beneficial effects of several medications for type 2 diabetes, as well as of those with bioactive molecules, on cognitive impairment in diabetic conditions. These findings could further highlight the therapeutic potential of these agents in treating Alzheimer’s disease and vascular cognitive impairment.

This Special Issue is focused on the current understanding and the future research directions concerning the mechanisms underlying the pathogenesis of and the preventive and/or treatment strategies for diabetes-related cognitive impairment. We warmly welcome original manuscripts, review articles, and commentaries relating to this hot topic.

Prof. Dr. Masashi Tanaka
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Alzheimer’s disease
• amyloid-hyperglycemia
• insulin resistance
• mitochondrial dysfunction
• cerebrovascular diseases
• metabolic diseases
• neuroinflammation
• tau hyperphosphorylation
• type 2 diabetes
• vascular cognitive impairment

• Diabetes and Dementia in International Journal of Molecular Sciences (8 articles)